EAM Investors LLC decreased its holdings in shares of Zogenix, Inc. (NASDAQ:ZGNX) by 20.0% in the fourth quarter, HoldingsChannel.com reports. The fund owned 107,287 shares of the company’s stock after selling 26,836 shares during the quarter. EAM Investors LLC’s holdings in Zogenix were worth $4,297,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds have also modified their holdings of the company. Alliancebernstein L.P. boosted its holdings in Zogenix by 16.3% in the 2nd quarter. Alliancebernstein L.P. now owns 17,812 shares of the company’s stock worth $258,000 after buying an additional 2,500 shares during the period. Teachers Advisors LLC boosted its holdings in Zogenix by 6.9% in the 2nd quarter. Teachers Advisors LLC now owns 44,555 shares of the company’s stock worth $646,000 after buying an additional 2,876 shares during the period. TIAA CREF Investment Management LLC boosted its holdings in Zogenix by 0.9% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 66,610 shares of the company’s stock worth $966,000 after buying an additional 608 shares during the period. Northern Trust Corp boosted its holdings in Zogenix by 15.3% in the 2nd quarter. Northern Trust Corp now owns 341,309 shares of the company’s stock worth $4,949,000 after buying an additional 45,219 shares during the period. Finally, Dimensional Fund Advisors LP boosted its holdings in Zogenix by 13.2% in the 2nd quarter. Dimensional Fund Advisors LP now owns 464,761 shares of the company’s stock worth $6,739,000 after buying an additional 54,120 shares during the period. 85.04% of the stock is owned by hedge funds and other institutional investors.
Zogenix, Inc. (NASDAQ ZGNX) opened at $44.45 on Tuesday. Zogenix, Inc. has a 1-year low of $8.50 and a 1-year high of $44.70. The company has a current ratio of 2.71, a quick ratio of 2.71 and a debt-to-equity ratio of 0.23.
In other Zogenix news, Director Roger Hawley sold 11,797 shares of the stock in a transaction dated Friday, December 8th. The shares were sold at an average price of $37.02, for a total transaction of $436,724.94. Following the completion of the transaction, the director now owns 105,575 shares of the company’s stock, valued at approximately $3,908,386.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Bradley S. Galer acquired 1,346 shares of the company’s stock in a transaction on Wednesday, December 13th. The shares were bought at an average cost of $36.59 per share, with a total value of $49,250.14. The disclosure for this purchase can be found here. 6.60% of the stock is owned by corporate insiders.
Zogenix Company Profile
Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome.
Want to see what other hedge funds are holding ZGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zogenix, Inc. (NASDAQ:ZGNX).
Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.